Transscleral delivery
US7585517B2 · kind B2 · utility
78Cited by
128References
31Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 20, 2004 |
| Grant date | Sep 8, 2009 |
| Priority date | — |
| Expiry date | Aug 28, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.